SOUTH
SAN FRANCISCO, Calif., July 26,
2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.
(Nasdaq: RIGL) today announced that it will report its second
quarter 2022 financial results after market close on Tuesday, August 2, 2022. Rigel senior
management will follow the announcement with a live conference call
and webcast at 4:30 p.m. Eastern Time
(1:30 p.m. Pacific Time) to discuss
the financial results and give an update on the business.
Participants can access the live conference call by dialing
877-407-3088 (domestic) or 201-389-0927 (international). The
conference call and accompanying slides will also be webcast live
and can be accessed from the Investor Relations section of the
company's website at www.rigel.com. The webcast will be
archived and available for replay for 90 days after the call via
the Rigel website.
About Rigel
Rigel Pharmaceuticals, Inc., is a
biotechnology company dedicated to discovering, developing and
providing novel small molecule drugs that significantly improve the
lives of patients with hematologic disorders, cancer and rare
immune diseases. Rigel's pioneering research focuses on signaling
pathways that are critical to disease mechanisms. The company's
first FDA approved product is TAVALISSE® (fostamatinib
disodium hexahydrate) tablets, the only oral spleen tyrosine kinase
(SYK) inhibitor for the treatment of adult patients with chronic
immune thrombocytopenia who have had an insufficient response to a
previous treatment. The product is also commercially available in
Europe, the United Kingdom (TAVLESSE) and Canada (TAVALISSE) for the treatment of
chronic immune thrombocytopenia in adult patients.
Fostamatinib is currently being studied in a Phase 3 clinical
trial (NCT03764618) for the treatment of warm autoimmune hemolytic
anemia (wAIHA)1; a Phase 3 clinical
trial (NCT04629703) for the treatment of
hospitalized high-risk patients with COVID-191; and an
NIH/NHLBI-sponsored Phase 3 clinical trial (ACTIV-4 Host Tissue
Trial, NCT04924660) for the treatment of COVID-19 in hospitalized
patients.
Rigel's other clinical programs include its interleukin
receptor-associated kinase (IRAK) inhibitor program, and a
receptor-interacting serine/threonine-protein kinase (RIPK)
inhibitor program in clinical development with partner Eli Lilly
and Company. In addition, Rigel has product candidates in
development with partners BerGenBio ASA and Daiichi Sankyo.
For further information, visit www.rigel.com or follow
us on Twitter or LinkedIn.
Please see www.TAVALISSE.com for the full
Prescribing Information.
1The product for this use or indication is
investigational and has not been proven safe or effective by any
regulatory authority.
Investor Contact:
Jodi Sievers
Rigel Pharmaceuticals, Inc.
Phone: 650.624.1232
Email: ir@rigel.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2022-financial-results-and-business-update-301592960.html
SOURCE Rigel Pharmaceuticals, Inc.